Angina Pectoris Treatment Market By Drug Type (Antiplatelet agents, Beta-adrenergic blocking agents, Calcium channel blockers, Short & Long – acting Nitroglycerines, Angiotensin-converting enzyme inhibitors, Anti-ischemic agents) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

This report on global angina pectoris treatment market studies various drugs used for treatment of angina pectoris along with pipeline analysis of upcoming potential drugs. Angina is chest pain due to transient myocardial ischaemia, which usually occurs with physical activity or emotional stress, in the United States 10.2 million are estimated to experience angina with approximately 500,000 new cases occurring each year. Thus, drug pipeline of angina pectoris treatment market comprises potential drugs which are specific and fast in therapeutic action. 

For the purpose of this study, the various drug classes studied include antiplatelet agents, beta-adrenergic blocking agents, calcium channel blockers, short & long – acting nitroglycerines angiotensin-converting enzyme inhibitors and anti-ischemic agents. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for angina pectoris treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global angina pectoris market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Angina Pectoris Treatment Market Portaiture
2.2 Global Angina Pectoris Treament Market, by Drug Class, 2015 (USD Mn)
2.3 Relativity Analysis: Global Angina Pectoris Treatment Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Angina Pectoris Treatment Market: Market Dynamics and Outlook
3.1 Angina Pectoris Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Angina Pectoris Treatment Market, 2015 (Value %)

Chapter 4 Global Angina Pectoris Treatment Market, By Drug Class
4.1 Preface
4.2 Antiplatelet agents
4.3 Beta-adrenergic blocking agents
4.4 Calcium channel blockers
4.5 Short & Long – acting Nitroglycerines
4.6 Angiotensin-converting enzyme inhibitors
4.7 Anti-ischemic agents
4.8 Pipeline Analysis
4.8.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.8.1.1 Dantonic/T89
4.8.1.2 RANCAD
4.8.1.3 Cilostazol
4.8.1.4 Bococizumab
4.8.1.5 Ticagrelor
4.8.1.6 Auto-CD34+ cells
4.8.1.7 Alirocumab
4.8.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Angina Pectoris Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa

Chapter 6 Company Profiles
6.1 Abbott Laboratories Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Astra Zeneca plc
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Bayer AG
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 Bristol-Myers Squibb Company
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 F. Hoffmann-La Roche Ltd.
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Forest Laboratories Inc.
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Gilead Sciences, Inc.
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 GlaxoSmithKline plc
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
.9 Novartis AG
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Pfizer Inc.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage
6.11 Sanofi SA
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List Of Table

TABLE 1 Global Angina Pectoris Treatment Market Revenue, by Drug Class, 2013 – 2022 (USD Mn)
TABLE 2 Global Angina Pectoris Treatment Marrket Revenue, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 North America Angina Pectoris Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 4 Europe Angina Pectoris Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 5 Asia - Pacific Angina Pectoris Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 8 Rest of the World Angina Pectoris Treatment Market Revenue, by Region, 2013 – 2022 (USD Mn)

List Of Figure

FIG. 1 Global Angina Pectoris Treatment Market, by Drug Class, 2015 (USD Mn)
FIG. 2 Relativity Analysis: Global Angina Pectoris Treatment Market, by Geography, 2015 & 2022 (USD Mn)
FIG. 3 Attractive Investment Proposition, Global Angina Pectoris Treatment Market, 2015
FIG. 4 Market Share Analysis: Global Angina Pectoris Treatment Market, 2015 (Value %)
FIG. 5 Global Antiplatelet agents Market for Angina Pectoris Treatment, 2013 – 2022 (USD Mn)
FIG. 6 Global Beta-adrenergic Blocking Agents Market for Angina Pectoris Treatment, 20137– 2022 (USD Mn)
FIG. 7 Global Calcium Channel Blockers Market for Angina Pectoris Treatment, 2013 –2022 (USD Mn)
FIG. 8 Global Short & Long – acting Nitroglycerines Market for Angina Pectoris Treatment, 2013 – 2022 (USD Mn)
FIG. 9 Global Angiotensin-Converting Enzyme Inhibitors Market for Angina Pectoris Treatment, 2013 – 2022 (USD Mn)
FIG. 10 Global Anti-ischemic agents Market for Angina Pectoris Treatment, 2013 – 2022 (USD Mn)
FIG 11 Pipeline Analysis: Global Dantonic/T89 Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 12 Pipeline Analysis: Global RANCAD Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 13 Pipeline Analysis: Global Cilostazol Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 14 Pipeline Analysis: Global Bococizumab Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 15 Pipeline Analysis: Global Ticagrelor Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 16 Pipeline Analysis: Global Auto-CD34+ cells Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG 17 Pipeline Analysis: Global Alirocumab Market for Angina Pectoris Treatment, Upto 2022 (USD Mn)
FIG. 18 Global U.S. Angina Pectoris Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 19 Global Canada Angina Pectoris Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 20 Global U.K Angina Pectoris Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 21 Global Germany Angina Pectoris Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 22 Global Rest of Europe Angina Pectoris Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 23 Global China Angina Pectoris Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 24 Global Japan Angina Pectoris Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 25 Global Rest of Asia Pacific Angina Pectoris Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 26 Global Latin America Angina Pectoris Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 27 Global Middle East and Africa Angina Pectoris Treatment Market Revenue, 2013 – 2022 (USD Mn)

Drug Class Segmentation Analysis

Angina pectoris is a temporary chest pain or discomfort as a result of decreased blood flow to the heart muscle which is medically not a heart attack but a sign of increased risk. According to The British journal of Cardiology, chronic stable angina pectoris affects around 2 – 4% of the population in western countries and it is associated with an estimated annual risk of death and non-fatal myocardial infarction (MI) of 1–2% and 3% respectively. Based on the drug class, the angina pectoris treatment market is segmented into:

• Antiplatelet agents
• Beta-adrenergic blocking agents
• Calcium channel blockers
• Short & Long – acting Nitroglycerines
• Angiotensin-converting enzyme (ACE) inhibitors
• Anti-ischemic agents

Beta adrenergic blocking agents are the first line drug for angina pectoris treatment. Beta adrenergic blocking agents is one of the major drug classes in angina pectoris treatment market because these agents improve oxygen supply and demand balance by reducing heart rate and blood pressure, decreasing end systolic stress and contractility and prolonging diastole, allowing more coronary flow. The major factors assisting its growth are the efficiency, fast onset of action, accessibility to patients and high patient compliance.

Geography Segmentation Analysis

For the purpose of this study, the global angina pectoris market is categorized into:

• North America
• Europe
• Asia Pacific
• Rest of the World

North America was observed as the largest market for angina pectoris treatment in the base year 2015. According to American College of Cardiology, chronic angina pectoris affects over seven million North Americans every year and despite optimal pharmacological and interventional therapies, 32% of these patients remain symptomatic from coronary artery disease (CAD). Rising prevalence of angina pectoris, obesity in young population, sedentary lifestyle, and rising awareness related to early diagnosis of angina pectoris are major factors assisting the growth of North America angina pectoris treatment market. Europe is the second largest market followed by Asia Pacific, considering the prevalence rate Europe surpasses Asia Pacific and it’s considered as the most attractive region in angina pectoris therapeutics industry. However, Asia Pacific is estimated to pace at an exceptional growth rate due to rising prevalence of angina pectoris, high awareness related to cardiovascular diseases and developing healthcare infrastructure.